Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Blockhead12-09

Arcellx (ACLX) stock reversed lower Monday despite positive results for its rival to Legend Biotech's (LGND) multiple myeloma treatment, Carvykti. ↑ X How To Buy Stocks: IBD's Four Pillars Of ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490774920?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2024/12/Stock-arcellx-01-shutt-150x150.jpg","is_english":true,"pubTime":"2024-12-09 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490774920","market":"us","top_or_hot":-1,"title":"Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.","media":"Blockhead","content":"<div>\n<p>Arcellx (ACLX) stock reversed lower Monday despite positive results for its rival to Legend Biotech's (LGND) multiple myeloma treatment, Carvykti.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of ...</p>\n\n<a href=\"https://www.investors.com/news/technology/arcellx-stock-legend-stock-multiple-myeloma-anito-cel-carvykti/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 23:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/arcellx-stock-legend-stock-multiple-myeloma-anito-cel-carvykti/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arcellx (ACLX) stock reversed lower Monday despite positive results for its rival to Legend Biotech's (LGND) multiple myeloma treatment, Carvykti.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of ...</p>\n\n<a href=\"https://www.investors.com/news/technology/arcellx-stock-legend-stock-multiple-myeloma-anito-cel-carvykti/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"https://www.investors.com/news/technology/arcellx-stock-legend-stock-multiple-myeloma-anito-cel-carvykti/","article_id":"2490774920","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/12/Stock-arcellx-01-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490774920","pubTimestamp":1733759435,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","BK4550":"红杉资本持仓","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4581":"高盛持仓","BK4504":"桥水持仓","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","JNJ":"强生","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","BK4568":"美国抗疫概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","GILD":"吉利德科学","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","BK4139":"生物科技","LGND":"Ligand Pharmaceuticals Inc.","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4566":"资本集团","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","ACLX":"ARCELLX, INC.","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4559":"巴菲特持仓","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC"},"translate_title":"Arcellx和Legend Bio进行多发性骨髓瘤疫苗注射。但只有一个领先。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACLX":1,"LGND":1,"JNJ":1,"GILD":1},"content_text":"Arcellx (ACLX) stock reversed lower Monday despite positive results for its rival to Legend Biotech's (LGND) multiple myeloma treatment, Carvykti.\n\n\n\n↑\nX\n\n\n\n\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nHow To Buy Stocks: IBD's Four Pillars Of Investing\n\n\n\n\nOn Sunday, Arcellx said 97% of patients responded to treatment with its CAR-T drug, anito-cel, up from 95% in its prior data cut.\nAcross 86 patients that could be evaluated, 62% had complete responses — meaning all evidence of their cancer disappeared. And 93% of patients lived for six months before their cancer worsened. By a year, that number was 79%.\nLeerink Partners analyst Daina Graybosch called the results a \"best-case efficacy scenario.\"\nShe also noted that Arcellx's Gilead Sciences (GILD)-partnered anito-cel could be safer than Legend's Carvykti, developed in partnership with Johnson & Johnson (JNJ). There were no cases of Parkinsonism among anito-cel recipients. Parkinsonism refers to a group of neurological movement problems. It cropped up in a single-digit percentage of Carvykti patients in Legend's clinical studies.\nIn morning trades, Arcellx stock reversed lower, falling dipping a fraction to 84. That pulled back from a premarket gain of nearly 9%. Legend stock, on the other hand, reversed its decline and popped 3.9% to 43.18.\nArcellx Stock: Rivaling Legend's Carvykti\nThe companies are bitter rivals in the multiple myeloma space. Over the weekend, Arcellx released the updated results from its anito-cel test at the same time Legend held an analyst meeting to discuss real-world use of Carvykti.\nIt's anyone's guess who will lead the space in the coming years.\nPart of the problem stems from the differences in Arcellx's and Legend's studies. Legend seemingly enrolled sicker patients with Arcellx, analysts said. But Arcellx's CAR-T drug looks safer.\n\"We expect debates on patient selection and delayed neurotoxicity events are likely to take years to resolve,\" Leerink's Graybosch said in a client note.\nThe investment bank has an outperform rating on Arcellx stock.\nReal-World Use Of Carvykti\nDuring the Legend event, two doctors discussed real-world use of Carvykti.\nOnly one patient out of the roughly 200 they've treated with Carvykti has experienced Parkinsonism.\nManagement of cytokine release syndrome, or CRS, is also improving in the commercial world. CRS is an inflammatory condition that occurs when the immune system becomes overactive. CAR-T drugs involve stoking the immune system and, so, commonly cause CRS.\nIn Arcellx's study, CRS occurred in 83% of patients. Just 2% had serious events. That topped the 95% and 4%, respectively, in Legend's Carvykti studies. But, in the real world, academic centers and aligning on how to treat CRS, RBC Capital Markets analyst Leonid Timashev said in a report.\nTimashev ultimately expects Carvykti to reach a peak $10 billion in sales. He expects $2 billion in sales next year, above Legend Biotech's own guidance for $1.9 billion.\nHe kept his outperform rating on Legend stock, but didn't list a rating for Arcellx stock.\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nNvidia-backed SoundHound Notches 61% Weekly Gain. Why Stock's Massive Rally Also Poses Risks.\nThe Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market\nFind The Best Long-Term Investments With IBD Long-Term Leaders\nOptions Trading: How To Start Using Options, How To Manage Risk\nWant To Get Quick Profits And Avoid Big Losses? Try SwingTrader","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490774920"}